Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

NCT00055692 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

NIH

Sponsor class

Conditions

Adult Primary Hepatocellular Carcinoma
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions

BIOLOGICAL: bevacizumab

Sponsor

National Cancer Institute (NCI)